CA3171890A1 - Compositions and therapeutic uses of cannabidiol - Google Patents

Compositions and therapeutic uses of cannabidiol

Info

Publication number
CA3171890A1
CA3171890A1 CA3171890A CA3171890A CA3171890A1 CA 3171890 A1 CA3171890 A1 CA 3171890A1 CA 3171890 A CA3171890 A CA 3171890A CA 3171890 A CA3171890 A CA 3171890A CA 3171890 A1 CA3171890 A1 CA 3171890A1
Authority
CA
Canada
Prior art keywords
cannabidiol
syndrome
gating
pharmaceutical composition
long
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3171890A
Other languages
English (en)
French (fr)
Inventor
Peter Charles RUBEN
Mohamed Amin FOUDA
Mohammad-Reza GHOVANLOO
Vishal Anant Jadhav
Dana A. Page
Koushik CHOUDHURY
Rusinova RADDA
Tejas PHATERPEKAR
Manit PATEL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dr Merchant Shreema
Original Assignee
Dr Merchant Shreema
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Merchant Shreema filed Critical Dr Merchant Shreema
Publication of CA3171890A1 publication Critical patent/CA3171890A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3171890A 2020-02-19 2021-02-19 Compositions and therapeutic uses of cannabidiol Pending CA3171890A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN202021007184 2020-02-19
IN202021007184 2020-02-19
IN202021013770 2020-03-29
IN202021013770 2020-03-29
PCT/IN2021/050159 WO2021165992A1 (en) 2020-02-19 2021-02-19 Compositions and therapeutic uses of cannabidiol

Publications (1)

Publication Number Publication Date
CA3171890A1 true CA3171890A1 (en) 2021-08-26

Family

ID=77391770

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3171890A Pending CA3171890A1 (en) 2020-02-19 2021-02-19 Compositions and therapeutic uses of cannabidiol

Country Status (9)

Country Link
US (1) US20230123654A1 (https=)
EP (1) EP4106870A4 (https=)
JP (1) JP2023516284A (https=)
CN (1) CN115916336A (https=)
AU (1) AU2021223191A1 (https=)
CA (1) CA3171890A1 (https=)
IL (1) IL295753A (https=)
WO (1) WO2021165992A1 (https=)
ZA (1) ZA202210355B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL296892A (en) * 2020-03-29 2022-12-01 Akseera Pharma Corp Interaction of sars-cov-2 proteins through a molecular or cellular mechanism of host cells and compounds for the treatment of covid -19
AU2021250462A1 (en) * 2020-04-02 2022-12-01 Incannex Healthcare Limited Methods and compositions for treating or preventing an inflammatory condition
WO2022122904A1 (en) * 2020-12-09 2022-06-16 Chanelle Mccoy Cbd Limited A delayed-release capsule of cannabidiol
AU2022204290A1 (en) * 2020-12-12 2023-07-27 Akseera Pharma Corp. Cannabidiol for augmenting vaccine mediated immunity and prophylaxis of covid-19
IL309886A (en) * 2021-07-15 2024-03-01 Incannex Healthcare Ltd A preparation containing cannabidiol and hydroxychloroquine in a combined capsule at a fixed dose
JPWO2024043242A1 (https=) * 2022-08-23 2024-02-29

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087374B2 (en) * 2003-06-26 2006-08-08 The Research Foundation Of State University Of New York Screen for sodium channel modulators
MX376077B (es) * 2013-03-13 2025-03-07 Univ Cincinnati Tratamiento de una disfuncion cardiaca diastolica con un agonista del receptor trpv2.
WO2016161138A1 (en) * 2015-03-31 2016-10-06 Stamets Paul Edward Antiviral activity from medicinal mushrooms and their active constituents
LT6486B (lt) * 2016-04-13 2018-01-10 UAB "SatiMed" Aliejinio gelio kompozicija su aktyviausiais junginiais iš c. sativa ir m. arvensis ir jos pateikimo sistema, skirta giliųjų audinių uždegimo ir skausmo mažinimui
IL262713B2 (en) * 2016-05-02 2024-07-01 Stero Biotechs Ltd Cannabidiol for reducing a steroid dose and treating inflammatory and autoimmune diseases
CN108079305A (zh) * 2016-11-23 2018-05-29 汉义生物科技（北京）有限公司 大麻二酚与三环类抗抑郁药的药物组合物及其用途
AU2018273410A1 (en) * 2017-05-26 2020-01-16 Altum Pharmaceuticals Inc. Biphasix cannabinoid delivery
US20210085801A1 (en) * 2017-12-12 2021-03-25 Cardiol Therapeutics Inc. Amphiphilic block copolymers, micelles, and methods for treating or preventing heart failure
KR102632946B1 (ko) * 2018-01-13 2024-02-05 트루티바 인코포레이티드 노화 방지 및 피부 톤 미백 조성물 및 이를 위한 방법
CN110575448A (zh) * 2018-06-08 2019-12-17 云南汉素生物科技有限公司 大麻二酚组合物及其用途
WO2020183456A1 (en) * 2019-03-10 2020-09-17 Bol Pharma Ltd. Cannabinoid combinations for treating chronic pain in dialysis patients

Also Published As

Publication number Publication date
AU2021223191A1 (en) 2022-10-13
CN115916336A (zh) 2023-04-04
IL295753A (en) 2022-10-01
JP2023516284A (ja) 2023-04-19
US20230123654A1 (en) 2023-04-20
WO2021165992A1 (en) 2021-08-26
EP4106870A4 (en) 2024-04-10
EP4106870A1 (en) 2022-12-28
ZA202210355B (en) 2024-02-28

Similar Documents

Publication Publication Date Title
US20230123654A1 (en) Compositions and therapeutic uses of cannabidiol
US10912744B2 (en) Therapeutic formulation for reduced drug side effects
US12514819B2 (en) Colchicine drug-to-drug interactions
US20240009132A1 (en) Cannabinoids in the treatment of autism spectrum disorder
ES2773834T3 (es) Métodos y composiciones para tratar la depresión usando ciclobenzaprina
WO2013059676A1 (en) Compositions for reduction of side effects
EA015483B1 (ru) ПРИМЕНЕНИЕ ИНГИБИТОРА p38 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ПСИХИАТРИЧЕСКИХ РАССТРОЙСТВ
AU2007334747A1 (en) Tablet formulation including macrocyclic lactone and levamisole anthelmintic agents
US20220304982A1 (en) System for enhancing therapeutic compliance of the anti-cancer compound e7766
US11071731B2 (en) Allosteric modulators of the mu opioid receptor
KR20240012533A (ko) 자가면역, 동종면역, 염증성 및 미토콘드리아 질환 치료용 조성물 및 이의 용도
AU2008360070A1 (en) Tablet manufacturing method
US20200069675A1 (en) Pharmaceutical preparations of sebacoyl dinalbuphine and acetaminophen and methods for treating pain
US20140051730A1 (en) Therapeutic use of dimiracetam to prevent the hand and foot syndrome caused by sorafenib
HK40077420A (zh) 一种抗抑郁和抗焦虑的取代桂皮酰胺化合物
WO2022247834A1 (zh) 一种抗抑郁和抗焦虑的取代桂皮酰胺化合物
CN121466010A (zh) 阿托西班组合物及其用途
CN119522109A (zh) 用于钙调磷酸酶抑制剂的间歇性给药的组合物
AU2014201152A1 (en) Tablet Formulation

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220929

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240712

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20240906

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20240927

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250207

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250207

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250307

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250307

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250307

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250812

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251029

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20251212